Developer docs
API playgroundTry for free, no card

Search company profiles

Grunenthal

Full company profile

uuid000293e

Namestring
Grunenthal
Legal namestring
Grünenthal GmbH
Websiteurl
grunenthal.de
Company typeenum
Private
Founded yearint
1946
Descriptiontext

Grünenthal is a privately held, research-focused pharmaceutical company headquartered in Aachen, Germany, specializing in pain management and related diseases. Founded in 1946 and family-controlled by the Wirtz family, the company employs approximately 4,400 people and operates through subsidiaries in 28 countries, with products available in approximately 100 countries. Its commercial portfolio centers on Qutenza®, a topical non-systemic, non-opioid capsaicin 8% patch for peripheral neuropathic pain (acquired in 2018), and Palexia® (tapentadol), an opioid analgesic available in multiple formulations including extended-release tablets and oral solutions. Supporting the commercial franchise are educational and professional services platforms — Grünenthal Campus (product information and study summaries for healthcare professionals) and Grünenthal PRO — together with co-sponsorship of long-standing pain research and palliative care awards with Deutsche Schmerzgesellschaft (since 1987) and Deutsche Gesellschaft für Palliativmedizin (since 2008).

Grünenthal generates revenue through pharmaceutical product sales across both opioid and non-opioid pain treatments, supplemented by international licensing partnerships that extend its reach into geographies without owned sales infrastructure. Distribution is conducted primarily through physician prescriptions, hospital pharmacies, and direct field sales to healthcare providers in the DACH region, Europe, Latin America, and the United States, with selective licensing agreements (such as the recent Clinect Pty Ltd arrangement for Qutenza® in Australia) covering additional markets. The company has historically pursued an M&A-driven growth strategy, exemplified by the 2018 Qutenza® acquisition and a past $11.75 billion joint bid with EQT for Organon & Co., and actively defends its intellectual property through regulatory and legal actions, including a December 2022 German injunction against generic Palexia® retard competitors.

Grünenthal reported revenue of €1.7 billion in 2022 with double-digit revenue growth and record sales announced for 2023. Beyond its commercial activities, the company maintains scientific partnerships, a Global Graduate Programme, and sustainability initiatives such as a 1.9 MWp solar installation at its Aachen campus commissioned in 2024. The company is recognized as a Great Place to Work employer in Germany and is a member of EFPIA and the Vfa.

Short descriptiontext

Grünenthal is a privately held, family-owned pharmaceutical company headquartered in Aachen, Germany, specializing in pain therapeutics. It sells the non-opioid Qutenza® patch and opioid Palexia® formulations to physicians and hospitals across approximately 100 countries via owned subsidiaries and licensing partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersAachen, Germany
HQ citystring
Aachen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pain management pharmaceuticals, neuropathic pain treatment, opioid analgesic development, topical capsaicin patches, prescription drug manufacturing
Industry2 codes
PRIMARYHLAIABAF
Ophthalmic & Otic Generics
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Ophthalmic Goods Merchant Wholesalers423460
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pain Management Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Grünenthal generates revenue through the development, manufacturing, and sale of pharmaceutical products, primarily focused on pain treatments and related conditions. The company reported revenue of 1.7 billion euros in 2022 with double-digit revenue growth.

grunenthal.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Pharmaceutical prescription products distributed through healthcare providers and pharmacies
ModelOther
Notes

Pricing determined by regulatory approvals, reimbursement negotiations, and market-specific healthcare policies

grunenthal.de
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Grünenthal is a research-focused pharmaceutical company that develops, manufactures, and commercializes prescription medications for pain management and related conditions. Its core commercial products are Qutenza®, a topical non-systemic, non-opioid capsaicin patch for peripheral neuropathic pain, and Palexia®, an opioid analgesic (tapentadol) available in extended-release and oral solution formulations. The company also operates healthcare-professional education and service platforms (Grünenthal Campus, Grünenthal PRO) supporting product adoption.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Record revenue of 1.7 billion EUR with double-digit growth in 2023
Product overview1 text field

Grünenthal is a research-focused pharmaceutical company specializing in pain treatment and related conditions. The company's product portfolio includes Qutenza® (topical non-opioid patch for neuropathic pain, acquired in 2018), Palexia® (opioid analgesic in extended-release and oral formulations), and supporting platforms like Grünenthal Campus for healthcare professional education. The company operates primarily in Europe with products available in approximately 100 countries.

Product and service2 records
1Qutenza®
CategoryPain management pharmaceutical — non-opioid topical patch
Description

Topical, non-systemic, non-opioid capsaicin patch indicated for the management of peripheral neuropathic pain. Distributed via physician prescription to healthcare providers and hospitals.

2Palexia® retard
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-24
Description

Grünenthal entered into a definitive agreement granting Clinect Pty Ltd exclusive Australian rights to Qutenza®, a topical non-systemic, non-opioid patch for peripheral neuropathic pain. Clinect is responsible for obtaining marketing authorisation in Australia and will handle marketing and distribution of the product. This aligns with Grünenthal's strategy to expand the global footprint of Qutenza®.

2Deutsche Schmerzgesellschaft e.V. (German Pain Society)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing partnership since 1987 where Grünenthal co-sponsors the annual Förderpreis für Schmerzforschung (Pain Research Funding Award). This partnership supports scientific work in applied and translational pain research.

grunenthal.de
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Since 2008, Grünenthal co-sponsors the Anerkennungs- und Förderpreis für Praxisinitiativen in der Palliativversorgung (Recognition and Funding Award for Palliative Care Initiatives) endowed with 10,000 euros.

4Solarimo GmbH
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Solarimo GmbH built and operates the largest solar installation in Aachen on Grünenthal's campus property. The approximately 4,000 solar modules with 1.9 MWp capacity will generate renewable energy and help Grünenthal achieve its 2030 carbon reduction targets.

grunenthal.de
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Mundipharma is a privately-held specialty pharmaceutical company focused on pain management and related therapies across global markets. It is one of the closest direct comparables to Grünenthal given the shared pain-focused portfolio, private ownership structure, and international commercialization footprint.

TypeDirect peer
Description

Purdue Pharma was a pain-management specialist built around opioid and non-opioid analgesics before its restructuring. Its product portfolio, prescriber relationships, and historical regulatory exposure make it a directly comparable, albeit cautionary, peer for Grünenthal's pain franchise.

TypeDirect peer
Description

Collegium Pharmaceutical is a US specialty pharma focused on responsible pain management, including abuse-deterrent formulations. Its pain-only focus and similar GTM targeting of pain specialists and prescribers make it a directly comparable peer in scale and strategy.

TypeDirect peer
Description

Mallinckrodt is a specialty pharmaceutical company with a significant branded pain portfolio and hospital-channel distribution. Overlap in therapeutic focus, prescriber base, and product types makes it a strong comparable to Grünenthal.

5Endo International
TypeDirect peer
Description

Endo International built a pain-focused specialty pharma franchise around branded and generic analgesics. The therapeutic overlap and US-centric commercialization approach make it directly comparable to Grünenthal's pain business, particularly around the Palexia franchise.

TypeRegional player
Description

Aché is a leading Brazilian pharmaceutical company with a meaningful pain and analgesic portfolio across Latin America. It is a regional peer in the same therapeutic category but serves primarily Latin American markets rather than competing directly in Europe.

TypeBroad incumbent
Description

Daiichi Sankyo is a major Japanese pharmaceutical company with established pain and analgesic product lines alongside broader therapeutic areas. Its pain portfolio offers a broad-incumbent comparable to Grünenthal's specialty focus.

TypeBroad incumbent
Description

Teva is a global pharmaceutical company with a large specialty and generics portfolio that includes pain medications. Comparable as a broad-incumbent player with overlapping pain therapy offerings and global commercialization capabilities.

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Grunenthal

Pain Management Pharmaceuticalsgrunenthal.de

Grünenthal is a privately held, family-owned pharmaceutical company headquartered in Aachen, Germany, specializing in pain therapeutics. It sells the non-opioid Qutenza® patch and opioid Palexia® formulations to physicians and hospitals across approximately 100 countries via owned subsidiaries and licensing partnerships.

What Grunenthal does

Grünenthal is a privately held, research-focused pharmaceutical company headquartered in Aachen, Germany, specializing in pain management and related diseases. Founded in 1946 and family-controlled by the Wirtz family, the company employs approximately 4,400 people and operates through subsidiaries in 28 countries, with products available in approximately 100 countries. Its commercial portfolio centers on Qutenza®, a topical non-systemic, non-opioid capsaicin 8% patch for peripheral neuropathic pain (acquired in 2018), and Palexia® (tapentadol), an opioid analgesic available in multiple formulations including extended-release tablets and oral solutions. Supporting the commercial franchise are educational and professional services platforms — Grünenthal Campus (product information and study summaries for healthcare professionals) and Grünenthal PRO — together with co-sponsorship of long-standing pain research and palliative care awards with Deutsche Schmerzgesellschaft (since 1987) and Deutsche Gesellschaft für Palliativmedizin (since 2008).

Grünenthal generates revenue through pharmaceutical product sales across both opioid and non-opioid pain treatments, supplemented by international licensing partnerships that extend its reach into geographies without owned sales infrastructure. Distribution is conducted primarily through physician prescriptions, hospital pharmacies, and direct field sales to healthcare providers in the DACH region, Europe, Latin America, and the United States, with selective licensing agreements (such as the recent Clinect Pty Ltd arrangement for Qutenza® in Australia) covering additional markets. The company has historically pursued an M&A-driven growth strategy, exemplified by the 2018 Qutenza® acquisition and a past $11.75 billion joint bid with EQT for Organon & Co., and actively defends its intellectual property through regulatory and legal actions, including a December 2022 German injunction against generic Palexia® retard competitors.

Grünenthal reported revenue of €1.7 billion in 2022 with double-digit revenue growth and record sales announced for 2023. Beyond its commercial activities, the company maintains scientific partnerships, a Global Graduate Programme, and sustainability initiatives such as a 1.9 MWp solar installation at its Aachen campus commissioned in 2024. The company is recognized as a Great Place to Work employer in Germany and is a member of EFPIA and the Vfa.

Grunenthal firmographics

Firmographics
Name
Grunenthal
Legal name
Grünenthal GmbH
Website
https://grunenthal.de
Company type
Private
Founded year
1946
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Grünenthal is a privately held, family-owned pharmaceutical company headquartered in Aachen, Germany, specializing in pain therapeutics. It sells the non-opioid Qutenza® patch and opioid Palexia® formulations to physicians and hospitals across approximately 100 countries via owned subsidiaries and licensing partnerships.
Ownership category
akta.pro rank

Grunenthal industry classification

Industry
Product category
Pain Management Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIABAF
Ophthalmic & Otic Generics
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pain management pharmaceuticals
  • Neuropathic pain treatment
  • Opioid analgesic development
  • Topical capsaicin patches
  • Prescription drug manufacturing

Where Grunenthal is headquartered

Location

Headquarters

HQ city
Aachen
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Grunenthal business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Grünenthal generates revenue through the development, manufacturing, and sale of pharmaceutical products, primarily focused on pain treatments and related conditions. The company reported revenue of 1.7 billion euros in 2022 with double-digit revenue growth.

Pricing tiers

ModelBillingPrice
Other—Pharmaceutical prescription products distributed through healthcare providers and pharmacies

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Grunenthal product offering

Product offering

Core offering

Grünenthal is a research-focused pharmaceutical company that develops, manufactures, and commercializes prescription medications for pain management and related conditions. Its core commercial products are Qutenza®, a topical non-systemic, non-opioid capsaicin patch for peripheral neuropathic pain, and Palexia®, an opioid analgesic (tapentadol) available in extended-release and oral solution formulations. The company also operates healthcare-professional education and service platforms (Grünenthal Campus, Grünenthal PRO) supporting product adoption.

Product overview

Grünenthal is a research-focused pharmaceutical company specializing in pain treatment and related conditions. The company's product portfolio includes Qutenza® (topical non-opioid patch for neuropathic pain, acquired in 2018), Palexia® (opioid analgesic in extended-release and oral formulations), and supporting platforms like Grünenthal Campus for healthcare professional education. The company operates primarily in Europe with products available in approximately 100 countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Qutenza® Topical, non-systemic, non-opioid capsaicin patch indicated for the management of peripheral neuropathic pain. Distributed via physician prescription to healthcare providers and hospitals.
  • Palexia® retard

Quantifiable outcome

  • Record revenue of 1.7 billion EUR with double-digit growth in 2023

Companies that use Grunenthal

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Grunenthal technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Grunenthal partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Clinect Pty LtdcoreChannel Partner/ Reseller/ Distributor · 24 February 2026Grünenthal entered into a definitive agreement granting Clinect Pty Ltd exclusive Australian rights to Qutenza®, a topical non-systemic, non-opioid patch for peripheral neuropathic pain. Clinect is responsible for obtaining marketing authorisation in Australia and will handle marketing and distribution of the product. This aligns with Grünenthal's strategy to expand the global footprint of Qutenza®.
  • Deutsche Schmerzgesellschaft e.V. (German Pain Society)coreStrategic or Co-development PartnerLong-standing partnership since 1987 where Grünenthal co-sponsors the annual Förderpreis für Schmerzforschung (Pain Research Funding Award). This partnership supports scientific work in applied and translational pain research.
  • Deutsche Gesellschaft für Palliativmedizin (DGP)coreStrategic or Co-development PartnerSince 2008, Grünenthal co-sponsors the Anerkennungs- und Förderpreis für Praxisinitiativen in der Palliativversorgung (Recognition and Funding Award for Palliative Care Initiatives) endowed with 10,000 euros.
  • Solarimo GmbHminorStrategic or Co-development PartnerSolarimo GmbH built and operates the largest solar installation in Aachen on Grünenthal's campus property. The approximately 4,000 solar modules with 1.9 MWp capacity will generate renewable energy and help Grünenthal achieve its 2030 carbon reduction targets.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Grunenthal competitors and assessment

Company assessment

Direct peers

  • Mundipharma International: Mundipharma is a privately-held specialty pharmaceutical company focused on pain management and related therapies across global markets. It is one of the closest direct comparables to Grünenthal given the shared pain-focused portfolio, private ownership structure, and international commercialization footprint.
  • Purdue Pharma: Purdue Pharma was a pain-management specialist built around opioid and non-opioid analgesics before its restructuring. Its product portfolio, prescriber relationships, and historical regulatory exposure make it a directly comparable, albeit cautionary, peer for Grünenthal's pain franchise.
  • Collegium Pharmaceutical: Collegium Pharmaceutical is a US specialty pharma focused on responsible pain management, including abuse-deterrent formulations. Its pain-only focus and similar GTM targeting of pain specialists and prescribers make it a directly comparable peer in scale and strategy.
  • Mallinckrodt plc: Mallinckrodt is a specialty pharmaceutical company with a significant branded pain portfolio and hospital-channel distribution. Overlap in therapeutic focus, prescriber base, and product types makes it a strong comparable to Grünenthal.
  • Endo International: Endo International built a pain-focused specialty pharma franchise around branded and generic analgesics. The therapeutic overlap and US-centric commercialization approach make it directly comparable to Grünenthal's pain business, particularly around the Palexia franchise.

Regional players

  • Aché Laboratórios Farmacêuticos: Aché is a leading Brazilian pharmaceutical company with a meaningful pain and analgesic portfolio across Latin America. It is a regional peer in the same therapeutic category but serves primarily Latin American markets rather than competing directly in Europe.

Broad incumbents

  • Daiichi Sankyo: Daiichi Sankyo is a major Japanese pharmaceutical company with established pain and analgesic product lines alongside broader therapeutic areas. Its pain portfolio offers a broad-incumbent comparable to Grünenthal's specialty focus.
  • Teva Pharmaceutical Industries: Teva is a global pharmaceutical company with a large specialty and generics portfolio that includes pain medications. Comparable as a broad-incumbent player with overlapping pain therapy offerings and global commercialization capabilities.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Grunenthal social profiles

Digital presence

Grunenthal financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Grunenthal leadership team

Management profile

Number of profiles

Profiles6 records

Grunenthal funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Grunenthal M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grunenthal

What does Grunenthal do?

Grünenthal is a research-focused pharmaceutical company that develops, manufactures, and commercializes prescription medications for pain management and related conditions. Its core commercial products are Qutenza®, a topical non-systemic, non-opioid capsaicin patch for peripheral neuropathic pain, and Palexia®, an opioid analgesic (tapentadol) available in extended-release and oral solution formulations. The company also operates healthcare-professional education and service platforms (Grünenthal Campus, Grünenthal PRO) supporting product adoption.

Is Grunenthal a public or private company?

Grunenthal is a private company. It is classified as family owned and is currently operating.

When was Grunenthal founded?

Grunenthal was founded in 1946. It employs 1,001 to 5,000 people.

Where is Grunenthal based?

Grunenthal is headquartered in Aachen, Germany, in the Europe region.

How does Grunenthal make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Grunenthal's main competitors?

Direct peers on record are Mundipharma International, Purdue Pharma, Collegium Pharmaceutical, Mallinckrodt plc and Endo International. Aché Laboratórios Farmacêuticos is listed as a regional player. Broad incumbents are Daiichi Sankyo and Teva Pharmaceutical Industries.

Does Grunenthal have an API?

No public API is recorded for Grunenthal.

What industry is Grunenthal in?

Grunenthal's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIABAF, Ophthalmic & Otic Generics, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals